A team of researchers has identified a new type of pulmonary ionocyte, which is the site of cystic fibrosis-causing CFTR gene activity. This discovery could lead to new therapeutic approaches by increasing CFTR activity in affected cells.
Researchers from Novartis and collaborators have discovered a novel drug candidate, KDU731, to combat the protozoan parasite Cryptosporidium, which causes cryptosporidiosis. This breakthrough offers hope for new treatment options against this disease, which currently has no effective treatments or vaccines.
Gerald F. Joyce, a renowned physician scientist, has been elected to the Institute of Medicine at the National Academy of Sciences. He joins Novartis as Director of the Genomics Institute, focusing on developing novel RNA and DNA enzymes for clinical diagnostics and therapeutics.
The Cancer Cell Line Encyclopedia provides comprehensive genetic and molecular information for nearly 1,000 human cancer cell lines. This publicly available data may help researchers identify patients who could benefit from specific drugs and advance cancer research.
Researchers at Novartis have discovered a new class of dual-acting antimalarial compounds, the imidazolopiperazines (IZPs), which target both liver and blood infections. These compounds attack the Plasmodium parasite at both stages in its reproduction cycle, showing promise as a next-generation treatment for malaria.
Researchers have discovered a novel compound, spiroindolone NITD609, effective against both strains of the malaria parasite and shows pharmacological properties compatible with a once-daily dosing regimen.
The Novartis 2010 Immunology Prizes were awarded to Professor Michael Bevan and Charles Dinarello, and Juerg Tschopp, for their contributions to basic and clinical immunology. The prizes recognize individual achievement and provide financial support for further research.